124
Participants
Start Date
August 29, 2019
Primary Completion Date
January 4, 2021
Study Completion Date
March 29, 2021
XF-73
XF-73 is a dicationic porphyrin derivative having potent bactericidal properties with a novel mode of action.
Placebo
Placebo to match XF-73 nasal gel for colour and viscosity.
Ltd Clinic LJ, Kutaisi
JSC Evex Hospitals, Tbilisi
Clinical Center of Serbia, Belgrade
Clinic for Cardiac Surgery, Institute for Cardiovascular Disease-Deinje, Belgrade
Clinical Center Nis, Niš
Institute for Cardiovascular Disease of Vojvodina, Kamenitz
University of Florida, Gainesville
MercyOne Iowa Heart Center, Des Moines
University of Missouri Health Care, Columbia
Ochsner Clinic Foundation, New Orleans
Memorial Hermann - Memorial City Medical Center, Houston
Snake River Research, PLLC, Pocatello
CHI Franciscan Research Center, Tacoma
Ltd Israel-Georgia Medical Research Clinic Helsicore, Tbilisi
"Ltd Open Heart", Tbilisi
Ltd Cardiology Clinic Guli, Tbilisi
Ltd Acad. G.Chapidze Emergency Cardiology Center, Tbilisi
Ltd Bokhua Memorial Cardiovascular Center, Tbilisi
Ltd Tbilisi Heart and Vascular Clinic, Tbilisi
Ltd Clinic Jerarsi, Tbilisi
Ltd Tbilisi Heart Center, Tbilisi
Lead Sponsor
Destiny Pharma Plc
INDUSTRY